Kim DDH, Novitzky-Basso I, Kim TS, Atenafu EG, et al. Optimal duration of imatinib treatment/deep molecular response for treatment-free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial. Br J Haematol 2021;193:779-791.
PMID: 33876423